TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27441478

Group type: EXPERIMENTAL
Intervention: Low dose melatonin treatment group (10mg capsule once daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High dose melatonin treatment group (20mg capsule once daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo-controlled group
Number of subjects: 45
Study: 25240493

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no AF detected)
Number of subjects: 30
Study: 21630255

Group type: EXPERIMENTAL
Intervention: Self-collected specimens using Cervista (Hologic)
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Endocervical specimens using Cervista (Hologic)
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Self-collected specimens using MALDI-TOF
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Endocervical specimens using MALDI-TOF
Number of subjects: 8556
Study: 19926386

Group type: EXPERIMENTAL
Intervention: Real time automated feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CPR without feedback
Number of subjects: 0
Study: 17669347

Group type: EXPERIMENTAL
Intervention: Pre-analytical parameters affecting proteomic analysis
Number of subjects: 0
Study: 16214452

Group type: EXPERIMENTAL
Intervention: Highest quintile of magnesium intake (median 433 mg/day)
Number of subjects: 39876
Study: 12120887

Group type: EXPERIMENTAL
Intervention: Raltitrexed (Tomudex)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nordic FLv regimen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 25
Study: 9734735

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intraduodenal saline infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Infusion of octreotide
Number of subjects: 8
Study: 8295285

Group type: EXPERIMENTAL
Intervention: Captopril, 50 mg, twice per day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 2738792

Group type: EXPERIMENTAL
Intervention: Elimination diet with double-blind, placebo-controlled oral food challenges
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Second rechallenge after 2 years
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Third rechallenge
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Major allergens (egg, milk, soy, wheat, peanut)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Total serum IgE and prick skin tests
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Skin test wheal size
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Initial challenge with skin symptoms
Number of subjects: 75
Study: 1092728

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: 100 mg indomethacin daily
Number of subjects: 50
Study: 31274533

Group type: EXPERIMENTAL
Intervention: PrEP initiation in serodiscordant partnerships
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination intervention of PrEP initiation and retention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled setting with randomly selected PrEP initiators
Number of subjects: 0
Study: 28689520

Group type: EXPERIMENTAL
Intervention: Terlipressin 12-hour therapy (Group-B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Terlipressin 72-hour therapy (Group-A)
Number of subjects: 90
Study: 25677353

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral therapy (CBT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 152
Study: 25038208

Group type: EXPERIMENTAL
Intervention: LOLA
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: rifaximin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: probiotics
Number of subjects: 124

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study: 22996863

Group type: EXPERIMENTAL
Intervention: Classical pain-visual analog scale (VAS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pleasantness-visual analog scale (VAS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs)
Number of subjects: 40
Study: 19942034

Group type: EXPERIMENTAL
Intervention: Multiple-patient simulation experiences
Number of subjects: 0
Study: 17563155

Group type: EXPERIMENTAL
Intervention: Self-statements (anxious self-talk)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Treatment for anxiety disorders (AD)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: States of mind ratio
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Positive and depressive cognitions
Number of subjects: 145
Study: 15702530

Group type: EXPERIMENTAL
Intervention: Routine practice of gastrointestinal surgery
Number of subjects: 379

Group type: COMPARATOR
Intervention: University hospitals
Number of subjects: 379
Study: 11544612

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 33

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 33
Study: 9625683

Group type: EXPERIMENTAL
Intervention: Ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 67
Study: 7839475

Group type: EXPERIMENTAL
Intervention: Inhaled racemic epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (greater than 0.6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroids (when intubation is necessary)
Number of subjects: 0
Study: 3203714

Group type: EXPERIMENTAL
Intervention: Emthexat 2.5 mg tablets
Number of subjects: 39

Group type: COMPARATOR
Intervention: Methotrexate 2.5 mg tablets
Number of subjects: 39
Study: 2197851

Group type: EXPERIMENTAL
Intervention: 50 g protein with 50 g glucose
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10 g protein with 50 g glucose
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30 g protein with 50 g glucose
Number of subjects: 7

Group type: COMPARATOR
Intervention: 50 g glucose alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Various amounts of protein with 50 g glucose
Number of subjects: 7
Study: 1096575

Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: L-DOPA
Number of subjects: 16
Study: 31739206

Group type: EXPERIMENTAL
Intervention: Commercial orthosis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Custom-made orthosis
Number of subjects: 24
Study: 30673020

Group type: EXPERIMENTAL
Intervention: Diuretics (chlorthalidone/amiloride)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 110
Study: 28431534

Group type: EXPERIMENTAL
Intervention: Spirulina platensis (500 mg, twice daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (starch pills, two daily)
Number of subjects: 64
Study: 26382243

Group type: EXPERIMENTAL
Intervention: DDD-80 pacing for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: DDD-60 pacing for 3 months
Number of subjects: 12
Study: 24940324

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium 75mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 42
Study: 21701422

Group type: EXPERIMENTAL
Intervention: Systemic EGF treatment initiated immediately after pneumonia onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic EGF treatment initiated 24 hours after pneumonia onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transgenic IFABP-EGF mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 19298949

Group type: EXPERIMENTAL
Intervention: Neutral participants generating properties for noun phrases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants instructed to describe images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants instructed to produce word associations
Number of subjects: 0
Study: 17200252

Group type: EXPERIMENTAL
Intervention: Heparin infusion (0.5 U/kg per hour)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 15482873

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including enforcement of regulations, education, and peer review in Hanoi and Bangkok.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Peer review in Hanoi and Bangkok after the intervention.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Regulatory intervention in Bangkok.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Peer review in Bangkok after the intervention.
Number of subjects: 146
Study: 11517129

Group type: EXPERIMENTAL
Intervention: ECWO plus CPAP (5)
Number of subjects: 19

Group type: COMPARATOR
Intervention: ECWO plus CPAP
Number of subjects: 19
Study: 9932161

Group type: EXPERIMENTAL
Intervention: MTHF (100 mg/m2 days 1-5 i.v. bolus) plus FU (400 mg/m2 days 1-5) given as i.v. bolus injection
Number of subjects: 82

Group type: COMPARATOR
Intervention: MTHF (100 mg/m2 days 1-5 i.v. bolus) plus FU (400 mg/m2 days 1-5) given as a two-hour infusion
Number of subjects: 82
Study: 7832178

Group type: EXPERIMENTAL
Intervention: Recruitment strategy 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment strategy 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment strategy 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment strategy 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment strategy 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment strategy 6
Number of subjects: 0
Study: 3403864

Group type: EXPERIMENTAL
Intervention: Cottonseed flour (double-blind, placebo-controlled food challenge)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (double-blind, placebo-controlled food challenge)
Number of subjects: 7
Study: 31625596

Group type: EXPERIMENTAL
Intervention: Stepped wedge cluster randomized trials with varying cluster sizes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stepped wedge cluster randomized trials with equal cluster sizes
Number of subjects: 0
Study: 29889748

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol and 100 mg progesterone
Number of subjects: 1845

Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol and 100 mg progesterone
Number of subjects: 1845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1845

Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol and 50 mg progesterone
Number of subjects: 1845

Group type: EXPERIMENTAL
Intervention: 0.25 mg estradiol and 50 mg progesterone
Number of subjects: 1845
Study: 26983396

Group type: EXPERIMENTAL
Intervention: LM + 30 g/day brown milled flaxseed for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lifestyle modification (LM)
Number of subjects: 50
Study: 24731416

Group type: EXPERIMENTAL
Intervention: UPPP with oral appliance (UA group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: UPPP only (U group)
Number of subjects: 30
Study: 22614152

Group type: EXPERIMENTAL
Intervention: Enalapril (0.1 to 0.30 mg/kg/day)
Number of subjects: 9
Study: 20375709

Group type: EXPERIMENTAL
Intervention: H5N1 vaccine (1.9 microg HA/AS03(B), 3.75 microg HA/AS03(B), and 3.75 microg HA/AS03(A))
Number of subjects: 51

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: H5N1 vaccine
Number of subjects: 51
Study: 17656620

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25, 50, 100, and 200 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg with high-fat meal
Number of subjects: 44
Study: 15767179

Group type: COMPARATOR
Intervention: Axillary lymphadenectomy with drains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axillary lymphadenectomy without drains
Number of subjects: 0
Study: 11824859

Group type: EXPERIMENTAL
Intervention: AVP-V1-antagonist (d(CH2)5Tyr(me)AVP; 0.5 mg; AVPi)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10472321

Group type: EXPERIMENTAL
Intervention: Implementation of guidelines for occupational rehabilitation
Number of subjects: 59
Study: 8678512

Group type: EXPERIMENTAL
Intervention: 5-FU and leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU and levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU alone or in combination with chemotherapeutic drugs
Number of subjects: 0
Study: 1855676

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy using a combination of 1:100,000 adrenaline and 5% ethanolamine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy after rebleeding in conservatively treated group
Number of subjects: 109
Study: 6661730

Group type: EXPERIMENTAL
Intervention: Cholinergic drugs (physostigmine, pyridostigmine bromide, edrophonium chloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs (scopolamine, orphenadrine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28425183

Group type: EXPERIMENTAL
Intervention: Teens experiencing 4+ major life events
Number of subjects: 178

Group type: COMPARATOR
Intervention: Fewer major life events
Number of subjects: 178
Study: 27465213

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 231)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Isoflurane (n = 233)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 464

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 464
Study: 24154560

Group type: EXPERIMENTAL
Intervention: vibroX (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: resistance training (n = 10)
Number of subjects: 21
Study: 22814048

Group type: EXPERIMENTAL
Intervention: Transepithelial PRK
Number of subjects: 66

Group type: COMPARATOR
Intervention: Alcohol-assisted PRK
Number of subjects: 66
Study: 20151251

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Na-HA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Corticosteroid (CS)
Number of subjects: 51
Study: 17684044

Group type: EXPERIMENTAL
Intervention: Hormone levels measured at baseline and again at 3 and 6 months (total, free, and bioavailable testosterone, dihydrotestosterone, SHBG, LH, dehydroepiandrosterone, dehydroepiandrosterone sulfate, estrone, estradiol, cortisol)
Number of subjects: 121
Study: 15589567

Group type: EXPERIMENTAL
Intervention: bupropion (150 mg, PO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: bupropion (open-label treatment for 8 weeks)
Number of subjects: 20
Study: 12182278

Group type: EXPERIMENTAL
Intervention: Small group, 6-session communally oriented HIV prevention intervention
Number of subjects: 935

Group type: COMPARATOR
Intervention: Yoked general health promotion intervention control
Number of subjects: 935

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: HIV prevention group
Number of subjects: 935
Study: 10219064

Group type: EXPERIMENTAL
Intervention: Stopping primary prophylaxis against Pneumocystis carinii pneumonia
Number of subjects: 262
Study: 7777105

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous cycle peritoneal dialysis (CCPD)
Number of subjects: 24
Study: 2321780

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 45
Study: 119198

Group type: EXPERIMENTAL
Intervention: idoxuridine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vidarabine (Ara‐A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: trifluorothymidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: acycloguanosine
Number of subjects: 0
Study: 31264007

Group type: EXPERIMENTAL
Intervention: ELCA plus DCB
Number of subjects: 40

Group type: COMPARATOR
Intervention: DCB alone
Number of subjects: 40
Study: 31203208

Group type: EXPERIMENTAL
Intervention: IntelliSpace Portal (ISP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: syngo.via method A
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: syngo.via method B (additional smoothing)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: syngo.via method C (adjusted settings)
Number of subjects: 35

Group type: COMPARATOR
Intervention: RAPID
Number of subjects: 35
Study: 28564569

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, Velpatasvir, and Voxilaprevir (150 patients in POLARIS-1)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, Velpatasvir, and Voxilaprevir (163 patients in POLARIS-4)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Sofosbuvir and Velpatasvir (151 patients in POLARIS-4)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo (150 patients in POLARIS-1)
Number of subjects: 482
Study: 25559818

Group type: EXPERIMENTAL
Intervention: Combination of trastuzumab and lapatinib
Number of subjects: 0
Study: 23692553

Group type: EXPERIMENTAL
Intervention: Once-daily extended-release topiramate (USL255)
Number of subjects: 0
Study: 21337293

Group type: EXPERIMENTAL
Intervention: Pharmaceutical consulting intervention by pharmacists regarding optimized antibiotic therapy
Number of subjects: 638

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Pharmaceutical consulting intervention
Number of subjects: 638
Study: 20034313

Group type: EXPERIMENTAL
Intervention: Wrist posture with flexion/extension and ulnar deviation
Number of subjects: 0
Study: 17204956

Group type: EXPERIMENTAL
Intervention: 75 mg 13C‐urea
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 125 mg 13C‐urea
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 13C‐urea blood test (both dosages)
Number of subjects: 40
Study: 15063432

Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3381
Study: 11204897

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg for males and 0.5 g/kg for females)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9744369

Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 994

Group type: COMPARATOR
Intervention: Enucleation alone
Number of subjects: 994
Study: 9083731

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide/oxygen mixture
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional sedation (pethidine 25-50 mg and midazolam 2.5 mg)
Number of subjects: 37
Study: 2022828

Group type: COMPARATOR
Intervention: Decompression of the transverse carpal ligament
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Decompression of the transverse carpal ligament with internal neurolysis of the median nerve
Number of subjects: 59
Study: 7148367

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 30
Study: 28825227

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for breast cancer
Number of subjects: 321
Study: 25706240

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1766
Study: 24717951

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 12 months
Number of subjects: 264

Group type: COMPARATOR
Intervention: No SLIT (control group)
Number of subjects: 264
Study: 22614882

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 95
Study: 19389245

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Focal Psychodynamic Therapy (FPT)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 237
Study: 17613112

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VaD-specific needling (additional to conventional acupuncture)
Number of subjects: 0
Study: 15223738

Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 12170445

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus carboplatin to an AUC of 6 every 3 weeks
Number of subjects: 1220

Group type: COMPARATOR
Intervention: vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 plus cisplatin 100 mg/m(2) on day 1 every 4 weeks
Number of subjects: 1220
Study: 9174680

Group type: EXPERIMENTAL
Intervention: Intravenous valsartan (5, 10, and 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral valsartan (80 mg capsule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral valsartan (buffered solution, 80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous valsartan (20 mg)
Number of subjects: 0
Study: 1606859

Group type: EXPERIMENTAL
Intervention: Suction-free drainages
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Drains with a long period of suction
Number of subjects: 40

Group type: COMPARATOR
Intervention: High vacuum drains
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups (including high vacuum, middle vacuum, low vacuum, suction-free)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suction-free and reduced vacuum drains
Number of subjects: 40
Study: 2859199

Group type: EXPERIMENTAL
Intervention: Bucindolol 150 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30395532

Group type: EXPERIMENTAL
Intervention: 100% volume exposure for 30 minutes through iPod Touch
Number of subjects: 40

Group type: COMPARATOR
Intervention: 75% volume exposure for 30 minutes through iPod Touch
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50% volume exposure for 30 minutes through iPod Touch
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0% volume exposure (no music) for 30 minutes through iPod Touch
Number of subjects: 40